|
US4307016A
(en)
*
|
1978-03-24 |
1981-12-22 |
Takeda Chemical Industries, Ltd. |
Demethyl maytansinoids
|
|
US4265814A
(en)
*
|
1978-03-24 |
1981-05-05 |
Takeda Chemical Industries |
Matansinol 3-n-hexadecanoate
|
|
JPS5562090A
(en)
*
|
1978-10-27 |
1980-05-10 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
|
JPS5566586A
(en)
*
|
1978-11-14 |
1980-05-20 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
|
JPS5566585A
(en)
*
|
1978-11-14 |
1980-05-20 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
|
US4256746A
(en)
*
|
1978-11-14 |
1981-03-17 |
Takeda Chemical Industries |
Dechloromaytansinoids, their pharmaceutical compositions and method of use
|
|
JPS55164687A
(en)
*
|
1979-06-11 |
1980-12-22 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
|
US4263294A
(en)
*
|
1978-11-20 |
1981-04-21 |
Takeda Chemical Industries, Ltd. |
Maytansinoids, pharmaceutical compositions thereof and method of use thereof
|
|
JPS55102583A
(en)
*
|
1979-01-31 |
1980-08-05 |
Takeda Chem Ind Ltd |
20-acyloxy-20-demethylmaytansinoid compound
|
|
JPS55162791A
(en)
*
|
1979-06-05 |
1980-12-18 |
Takeda Chem Ind Ltd |
Antibiotic c-15003pnd and its preparation
|
|
JPS55164685A
(en)
*
|
1979-06-08 |
1980-12-22 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
|
JPS55164686A
(en)
*
|
1979-06-11 |
1980-12-22 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
|
JPS5622790A
(en)
*
|
1979-07-31 |
1981-03-03 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
|
JPS5645483A
(en)
*
|
1979-09-19 |
1981-04-25 |
Takeda Chem Ind Ltd |
C-15003phm and its preparation
|
|
US4315929A
(en)
*
|
1981-01-27 |
1982-02-16 |
The United States Of America As Represented By The Secretary Of Agriculture |
Method of controlling the European corn borer with trewiasine
|
|
US5208020A
(en)
*
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
EP2803367B1
(en)
|
1999-06-25 |
2018-01-31 |
ImmunoGen, Inc. |
Methods of treatment using anti-ERBB antibody-maytansinoid conjugates
|
|
EP1229934B1
(en)
|
1999-10-01 |
2014-03-05 |
Immunogen, Inc. |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
|
|
US7097840B2
(en)
|
2000-03-16 |
2006-08-29 |
Genentech, Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
|
WO2002092771A2
(en)
|
2001-05-11 |
2002-11-21 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
|
US20110313230A1
(en)
|
2001-05-11 |
2011-12-22 |
Terrance Grant Johns |
Specific binding proteins and uses thereof
|
|
US6441163B1
(en)
|
2001-05-31 |
2002-08-27 |
Immunogen, Inc. |
Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
|
|
US20070160576A1
(en)
|
2001-06-05 |
2007-07-12 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides and therapeutic uses thereof
|
|
US20050107595A1
(en)
*
|
2001-06-20 |
2005-05-19 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
|
US7803915B2
(en)
*
|
2001-06-20 |
2010-09-28 |
Genentech, Inc. |
Antibody compositions for the diagnosis and treatment of tumor
|
|
KR100576674B1
(ko)
|
2001-06-20 |
2006-05-10 |
제넨테크, 인크. |
종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
|
|
US20040235068A1
(en)
*
|
2001-09-05 |
2004-11-25 |
Levinson Arthur D. |
Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
|
|
US20080085283A1
(en)
*
|
2001-09-05 |
2008-04-10 |
Levinson Arthur D |
Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
|
|
ATE516042T1
(de)
|
2001-09-18 |
2011-07-15 |
Genentech Inc |
Zusammensetzungen und verfahren zur behandlung und diagnose von tumoren
|
|
US20110045005A1
(en)
|
2001-10-19 |
2011-02-24 |
Craig Crowley |
Compositions and methods for the treatment of tumor of hematopoietic origin
|
|
KR20080106369A
(ko)
|
2002-01-02 |
2008-12-04 |
제넨테크, 인크. |
종양의 진단 및 치료 방법 및 이를 위한 조성물
|
|
KR20040101502A
(ko)
|
2002-04-16 |
2004-12-02 |
제넨테크, 인크. |
종양의 진단 및 치료 방법 및 이를 위한 조성물
|
|
US20090068178A1
(en)
*
|
2002-05-08 |
2009-03-12 |
Genentech, Inc. |
Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
|
|
WO2003106659A2
(en)
*
|
2002-06-18 |
2003-12-24 |
Archemix Corp. |
Aptamer-toxin molecules and methods for using same
|
|
US20040249130A1
(en)
*
|
2002-06-18 |
2004-12-09 |
Martin Stanton |
Aptamer-toxin molecules and methods for using same
|
|
US7767803B2
(en)
|
2002-06-18 |
2010-08-03 |
Archemix Corp. |
Stabilized aptamers to PSMA and their use as prostate cancer therapeutics
|
|
US8853376B2
(en)
|
2002-11-21 |
2014-10-07 |
Archemix Llc |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
|
US7432088B2
(en)
|
2003-05-08 |
2008-10-07 |
Immunogen Inc. |
Methods for the production of ansamitocins
|
|
EP1633784B1
(en)
|
2003-05-09 |
2011-07-13 |
Diadexus, Inc. |
Ovr110 antibody compositions and methods of use
|
|
US8088387B2
(en)
*
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
|
MX340862B
(es)
|
2003-05-20 |
2016-07-28 |
Immunogen Inc |
Agentes citotóxicos mejorados que comprenden nuevos maitansinoides.
|
|
CN104059147A
(zh)
|
2003-06-27 |
2014-09-24 |
艾默根佛蒙特有限公司 |
针对表皮生长因子受体的缺失突变体的抗体及其使用
|
|
EP2277908A3
(en)
|
2003-07-08 |
2011-12-14 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides, antibodies and therapeutic uses thereof
|
|
WO2005012531A2
(en)
*
|
2003-08-01 |
2005-02-10 |
Genentech, Inc. |
Antibody cdr polypeptide sequences with restricted diversity
|
|
PT2295073E
(pt)
|
2003-11-17 |
2014-07-16 |
Genentech Inc |
Anticorpo contra cd22 para o tratamento de tumor de origem hematopoiética
|
|
ZA200604864B
(en)
|
2003-12-19 |
2007-10-31 |
Genentech Inc |
Monovalent antibody fragments useful as therapeutics
|
|
EP2286844A3
(en)
*
|
2004-06-01 |
2012-08-22 |
Genentech, Inc. |
Antibody-drug conjugates and methods
|
|
AU2005269716B2
(en)
|
2004-07-20 |
2011-01-27 |
Genentech, Inc. |
Inhibitors of angiopoietin-like 4 protein, combinations, and their use
|
|
BRPI0512482A
(pt)
|
2004-07-26 |
2008-03-11 |
Genentech Inc |
método de identificação de uma substáncia inibidora candidata e molécula antagonista
|
|
CA2486285C
(en)
*
|
2004-08-30 |
2017-03-07 |
Viktor S. Goldmakher |
Immunoconjugates targeting syndecan-1 expressing cells and use thereof
|
|
AU2005279720B2
(en)
|
2004-09-03 |
2011-07-28 |
Genentech, Inc. |
Humanized anti-beta7 antagonists and uses therefor
|
|
JP2008526883A
(ja)
|
2005-01-07 |
2008-07-24 |
ディアデクサス インコーポレーテッド |
Ｏｖｒ１１０抗体組成物および使用方法
|
|
EP1863828A4
(en)
*
|
2005-03-07 |
2010-10-13 |
Archemix Corp |
STABILIZED APTAMERS FOR PSMA AND THEIR USE AS PROSTATE ACID THERAPEUTICS
|
|
EP1871163A2
(en)
|
2005-06-06 |
2008-01-02 |
Genentech, Inc. |
Transgenic models for different genes and their use for gene characterization
|
|
JP2009504183A
(ja)
|
2005-08-15 |
2009-02-05 |
ジェネンテック・インコーポレーテッド |
遺伝子破壊、それに関連する組成物および方法
|
|
EA013327B1
(ru)
|
2005-08-24 |
2010-04-30 |
Иммуноджен, Инк. |
Способ приготовления очищенных конъюгатов лекарственных средств
|
|
ES2577292T3
(es)
|
2005-11-07 |
2016-07-14 |
Genentech, Inc. |
Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
|
|
EP1962584A2
(en)
|
2005-11-21 |
2008-09-03 |
Genentech, Inc. |
Novel gene disruptions, compositions and methods relating thereto
|
|
RU2470941C2
(ru)
*
|
2005-12-02 |
2012-12-27 |
Дженентек, Инк. |
Связывающие полипептиды и их применения
|
|
RU2426742C2
(ru)
|
2005-12-02 |
2011-08-20 |
Дженентек, Инк. |
Составы и способы лечения заболеваний и нарушений, связанных с передачей сигналов цитокинами
|
|
EP1973951A2
(en)
*
|
2005-12-02 |
2008-10-01 |
Genentech, Inc. |
Binding polypeptides with restricted diversity sequences
|
|
CN103396485B
(zh)
|
2005-12-15 |
2016-08-10 |
健泰科生物技术公司 |
靶向多聚泛蛋白的方法和组合物
|
|
WO2007130697A2
(en)
|
2006-01-05 |
2007-11-15 |
Genentech, Inc. |
Anti-ephb4 antibodies and methods using same
|
|
EP1806365A1
(en)
|
2006-01-05 |
2007-07-11 |
Boehringer Ingelheim International GmbH |
Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
|
|
CN103193885B
(zh)
|
2006-01-20 |
2015-05-13 |
健泰科生物技术公司 |
抗ephrinb2抗体及其使用方法
|
|
CA2638821A1
(en)
|
2006-02-17 |
2007-10-11 |
Genentech, Inc. |
Gene disruptons, compositions and methods relating thereto
|
|
AR059851A1
(es)
|
2006-03-16 |
2008-04-30 |
Genentech Inc |
Anticuerpos de la egfl7 y metodos de uso
|
|
EP2614839A3
(en)
|
2006-04-05 |
2015-01-28 |
Genentech, Inc. |
Method for using BOC/CDO to modulate hedgehog signaling
|
|
EP2082645A1
(en)
|
2006-04-19 |
2009-07-29 |
Genentech, Inc. |
Novel gene disruptions, compositions and methods relating thereto
|
|
CN103030696B
(zh)
|
2006-05-30 |
2016-09-28 |
健泰科生物技术公司 |
抗体和免疫偶联物及其用途
|
|
ES2530438T3
(es)
|
2006-09-12 |
2015-03-02 |
Genentech Inc |
Procedimientos y composiciones para el diagnóstico y tratamiento del cáncer de pulmón utilizando el gen de KIT o KDR como marcador genético
|
|
US8436147B2
(en)
|
2006-10-27 |
2013-05-07 |
Genentech, Inc. |
Antibodies and immunoconjugates and uses therefor
|
|
WO2008067283A2
(en)
|
2006-11-27 |
2008-06-05 |
Diadexus, Inc. |
Ovr110 antibody compositions and methods of use
|
|
MX338185B
(es)
*
|
2007-01-25 |
2016-04-05 |
Dana Farber Cancer Inst Inc |
Uso de anticuerpos anti-egfr en el tratamiento de enfermedad mediada por egfr mutante.
|
|
EP2125896A2
(en)
|
2007-02-09 |
2009-12-02 |
Genetech, Inc. |
Anti-robo4 antibodies and uses therefor
|
|
CA2680854C
(en)
*
|
2007-03-15 |
2017-02-14 |
Ludwig Institute For Cancer Research |
Treatment method using egfr antibodies and src inhibitors and related formulations
|
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
|
PE20090321A1
(es)
|
2007-06-04 |
2009-04-20 |
Genentech Inc |
Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
|
|
SI2474557T1
(sl)
|
2007-07-16 |
2014-12-31 |
Genentech, Inc. |
Protiteles proti CD79b in imunokonjugati in postopki za uporabo
|
|
CN101802013B
(zh)
|
2007-07-16 |
2014-07-02 |
健泰科生物技术公司 |
人源化抗cd79b抗体和免疫偶联物及使用方法
|
|
MX2010001757A
(es)
|
2007-08-14 |
2010-09-14 |
Ludwig Inst Cancer Res |
Anticuerpo monoclonal 175 que activa el receptor egf y derivados y usos del mismo.
|
|
WO2010135521A2
(en)
|
2009-05-20 |
2010-11-25 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
|
US20110033476A1
(en)
*
|
2007-11-12 |
2011-02-10 |
Theraclone Sciences Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
|
AU2008321016B2
(en)
|
2007-11-12 |
2013-03-28 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
|
TWI468417B
(zh)
|
2007-11-30 |
2015-01-11 |
Genentech Inc |
抗－ｖｅｇｆ抗體
|
|
US9387261B2
(en)
*
|
2007-12-26 |
2016-07-12 |
Biotest Ag |
Immunoconjugates targeting CD138 and uses thereof
|
|
WO2009080829A1
(en)
*
|
2007-12-26 |
2009-07-02 |
Biotest Ag |
Agents targeting cd138 and uses thereof
|
|
RU2486203C2
(ru)
*
|
2007-12-26 |
2013-06-27 |
Биотест Аг |
Способы улучшения направленного воздействия на cd138-экспрессирующие опухолевые клетки и агенты для их осуществления
|
|
WO2009080831A1
(en)
*
|
2007-12-26 |
2009-07-02 |
Biotest Ag |
Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates
|
|
WO2009126350A2
(en)
|
2008-01-18 |
2009-10-15 |
Genentech, Inc. |
Methods and compositions for targeting polyubiquitin
|
|
EP2247620B1
(en)
|
2008-01-31 |
2016-05-18 |
Genentech, Inc. |
Anti-cd79b antibodies and immunoconjugates and methods of use
|
|
CN102015766B
(zh)
|
2008-03-10 |
2014-07-16 |
特罗科隆科学有限公司 |
用于对巨细胞病毒感染进行治疗以及诊断的组合物以及方法
|
|
CA2716592C
(en)
|
2008-03-18 |
2018-02-27 |
Genentech, Inc. |
Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
|
|
EP3208612B1
(en)
|
2008-04-09 |
2019-09-18 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
|
PL2279004T3
(pl)
*
|
2008-05-16 |
2015-06-30 |
Hoffmann La Roche |
Zastosowanie biomarkerów do oceny leczenia zaburzeń zapalnych przewodu pokarmowego antagonistami integryny beta7
|
|
JP5986745B2
(ja)
|
2008-07-15 |
2016-09-06 |
アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ |
Ｐｔｆｅ様のアルミニウム・コート・ガラススライド上のグリカンアレイおよび関連する方法
|
|
RU2580029C2
(ru)
|
2008-10-01 |
2016-04-10 |
Дженентек, Инк. |
Антитела против notch2 и способы их применения
|
|
US20120027722A1
(en)
|
2008-12-17 |
2012-02-02 |
Medical Research Council |
Hepatitis c virus combination therapy
|
|
SI3260136T1
(sl)
|
2009-03-17 |
2021-05-31 |
Theraclone Sciences, Inc. |
Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
|
|
PE20120539A1
(es)
|
2009-03-20 |
2012-05-12 |
Genentech Inc |
Anticuerpos anti-her biespecifico
|
|
MX345909B
(es)
|
2009-03-25 |
2017-02-22 |
Genentech Inc |
Anticuerpos anti-fgfr3 y métodos que los utilizan.
|
|
MA33256B1
(fr)
|
2009-04-01 |
2012-05-02 |
Genentech Inc |
Anticorps et immunoconjugués anti-fcrh5 et procédés d'utilisation
|
|
WO2010112193A1
(en)
|
2009-04-02 |
2010-10-07 |
Roche Glycart Ag |
Multispecific antibodies comprising full length antibodies and single chain fab fragments
|
|
SG175305A1
(en)
*
|
2009-04-23 |
2011-11-28 |
Theraclone Sciences Inc |
Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
|
|
CN102448500A
(zh)
|
2009-06-03 |
2012-05-09 |
免疫基因公司 |
轭合方法
|
|
EP2711018A1
(en)
|
2009-06-22 |
2014-03-26 |
MedImmune, LLC |
Engineered Fc regions for site-specific conjugation
|
|
KR20120089253A
(ko)
|
2009-07-31 |
2012-08-09 |
제넨테크, 인크. |
Ｂｖ８? 또는 ｇ?ｃｓｆ?길항제를 이용한 종양 전이의 억제
|
|
ES2599076T3
(es)
|
2009-09-02 |
2017-01-31 |
Genentech, Inc. |
Smoothened mutante y métodos de utilización del mismo
|
|
NZ598962A
(en)
|
2009-09-16 |
2014-12-24 |
Genentech Inc |
Coiled coil and/or tether containing protein complexes and uses thereof
|
|
US20110076232A1
(en)
|
2009-09-29 |
2011-03-31 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
|
AR078471A1
(es)
|
2009-10-02 |
2011-11-09 |
Sanofi Aventis |
COMPUESTOS MAITANSINOIDES Y EL USO DE ESTOS PARA PREPARAR CONJUGADOS CON UN ANTICUERPO LOS CUALES SE UTILIZAN COMO AGENTES ANTICANCERIGENOS Y EL PROCEDIMIENTO DE PREPARACIoN DE ESTOS CONJUGADOS
|
|
US8759491B2
(en)
|
2009-10-19 |
2014-06-24 |
Genentech, Inc. |
Modulators of hepatocyte growth factor activator
|
|
EP2490718B1
(en)
|
2009-10-22 |
2016-01-13 |
F.Hoffmann-La Roche Ag |
Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
|
|
AU2010310585A1
(en)
|
2009-10-22 |
2012-05-03 |
Genentech, Inc. |
Anti-hepsin antibodies and methods using same
|
|
WO2011056494A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
|
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
|
JP6173690B2
(ja)
|
2009-11-05 |
2017-08-02 |
ジェネンテック， インコーポレイテッド |
異種ポリペプチドの分泌のための方法及び組成物
|
|
JP5856065B2
(ja)
|
2009-11-30 |
2016-02-09 |
ジェネンテック， インコーポレイテッド |
腫瘍の診断と治療のための組成物と方法
|
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
|
US8486397B2
(en)
|
2009-12-11 |
2013-07-16 |
Genentech, Inc. |
Anti-VEGF-C antibodies and methods using same
|
|
US8771685B2
(en)
|
2009-12-23 |
2014-07-08 |
F. Hoffmann-La Roche Ag |
Anti-BV8 antibodies and uses thereof
|
|
WO2011082187A1
(en)
|
2009-12-30 |
2011-07-07 |
Genentech, Inc. |
Methods for modulating a pdgf-aa mediated biological response
|
|
RU2595389C2
(ru)
|
2010-02-23 |
2016-08-27 |
Дженентек, Инк. |
Композиции и способы для диагностики и лечения опухолей
|
|
AR080793A1
(es)
|
2010-03-26 |
2012-05-09 |
Roche Glycart Ag |
Anticuerpos biespecificos
|
|
WO2011130332A1
(en)
|
2010-04-12 |
2011-10-20 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
|
TWI586806B
(zh)
|
2010-04-23 |
2017-06-11 |
建南德克公司 |
異多聚體蛋白質之製造
|
|
SG185027A1
(en)
|
2010-05-03 |
2012-11-29 |
Genentech Inc |
Compositions and methods for the diagnosis and treatment of tumor
|
|
SG185430A1
(en)
|
2010-06-03 |
2012-12-28 |
Genentech Inc |
Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
|
|
AU2011289275A1
(en)
|
2010-08-12 |
2013-02-21 |
Theraclone Sciences, Inc. |
Anti-hemagglutinin antibody compositions and methods of use thereof
|
|
CN103068846B9
(zh)
|
2010-08-24 |
2016-09-28 |
弗·哈夫曼-拉罗切有限公司 |
包含二硫键稳定性Fv片段的双特异性抗体
|
|
ES2920140T3
(es)
|
2010-08-31 |
2022-08-01 |
Theraclone Sciences Inc |
Anticuerpos neutralizantes del virus de la inmunodeficiencia humana (VIH)
|
|
RU2013115927A
(ru)
|
2010-09-10 |
2014-10-20 |
Апексиджен, Инк. |
АНТИТЕЛА ПРОТИВ ИЛ-1β И СПОСОБЫ ПРИМЕНЕНИЯ
|
|
EP2625197B1
(en)
|
2010-10-05 |
2016-06-29 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
|
ES2544608T3
(es)
|
2010-11-17 |
2015-09-02 |
Genentech, Inc. |
Conjugados de anticuerpo y de alaninil-maitansinol
|
|
SG191153A1
(en)
|
2010-12-23 |
2013-07-31 |
Hoffmann La Roche |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
|
EP2670776B1
(en)
|
2011-02-04 |
2018-11-21 |
F. Hoffmann-La Roche AG |
Fc VARIANTS AND METHODS FOR THEIR PRODUCTION
|
|
US10689447B2
(en)
|
2011-02-04 |
2020-06-23 |
Genentech, Inc. |
Fc variants and methods for their production
|
|
EP2675478A4
(en)
|
2011-02-14 |
2015-06-10 |
Theraclone Sciences Inc |
COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF GRIP
|
|
JP6097702B2
(ja)
|
2011-03-03 |
2017-03-15 |
アペクシジェン， インコーポレイテッド |
抗ｉｌ−６受容体抗体およびその使用方法
|
|
MX2013010367A
(es)
|
2011-03-15 |
2014-04-14 |
Theraclone Sciences Inc |
Composiciones y metodos para la terapia y diagnostico de influenza.
|
|
EP2691155B1
(en)
|
2011-03-29 |
2018-11-14 |
Immunogen, Inc. |
Preparation of maytansinoid antibody conjugates by a one-step process
|
|
ES2709654T3
(es)
|
2011-04-29 |
2019-04-17 |
Apexigen Inc |
Anticuerpos anti-CD40 y métodos de uso
|
|
SG194735A1
(en)
|
2011-05-09 |
2013-12-30 |
Univ Virginia Patent Found |
Compositions and methods for treating cancer
|
|
HRP20231066T1
(hr)
|
2011-05-27 |
2023-10-27 |
Glaxo Group Limited |
Bcma (cd269/tnfrsf17) - vezujući proteini
|
|
EP2744825A1
(en)
|
2011-08-17 |
2014-06-25 |
F.Hoffmann-La Roche Ag |
Inhibition of angiogenesis in refractory tumors
|
|
US8822651B2
(en)
|
2011-08-30 |
2014-09-02 |
Theraclone Sciences, Inc. |
Human rhinovirus (HRV) antibodies
|
|
JO3625B1
(ar)
|
2011-09-22 |
2020-08-27 |
Amgen Inc |
بروتينات رابطة للأنتيجين cd27l
|
|
EP2776051A4
(en)
|
2011-10-28 |
2015-06-17 |
Hoffmann La Roche |
THERAPEUTIC COMBINATIONS AND METHOD FOR THE TREATMENT OF MELANOMA
|
|
EP2785742B1
(en)
|
2011-11-02 |
2020-01-08 |
Apexigen, Inc. |
Anti-kdr antibodies and methods of use
|
|
CN104168922A
(zh)
|
2011-11-16 |
2014-11-26 |
安姆根有限公司 |
治疗表皮生长因子缺失突变体viii相关疾病的方法
|
|
BR112014013694A2
(pt)
|
2011-12-08 |
2017-06-13 |
Biotest Ag |
método para tratar uma doença, e, kit
|
|
EP3539982B1
(en)
|
2011-12-23 |
2025-02-19 |
Pfizer Inc. |
Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
|
|
AU2013208007A1
(en)
|
2012-01-09 |
2014-07-31 |
The Scripps Research Institute |
Humanized antibodies with ultralong CDR3
|
|
EP2802603A4
(en)
|
2012-01-09 |
2015-11-04 |
Scripps Research Inst |
REGIONS DETERMINING ULTRALONGUAL COMPLEMENTARYITY AND USES THEREOF
|
|
CA2861124A1
(en)
|
2012-02-10 |
2013-08-15 |
Genentech, Inc. |
Single-chain antibodies and other heteromultimers
|
|
US20140170159A9
(en)
|
2012-03-08 |
2014-06-19 |
Ge Wei |
Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
|
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
|
SG11201407106XA
(en)
|
2012-05-01 |
2014-11-27 |
Genentech Inc |
Anti-pmel17 antibodies and immunoconjugates
|
|
UY34813A
(es)
|
2012-05-18 |
2013-11-29 |
Amgen Inc |
Proteínas de unión a antígeno dirigidas contra el receptor st2
|
|
KR20150023889A
(ko)
|
2012-06-27 |
2015-03-05 |
에프. 호프만-라 로슈 아게 |
2 개 이상의 상이한 결합 단위를 함유하는 맞춤-제작된 고도로 선별적이고 다중-특이적인 표적화 단위의 선별 및 제조 방법 및 이의 용도
|
|
CA2871882A1
(en)
|
2012-06-27 |
2014-01-03 |
F. Hoffmann-La Roche Ag |
Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
|
|
CA2880701A1
(en)
|
2012-08-18 |
2014-02-27 |
Academia Sinica |
Cell-permeable probes for identification and imaging of sialidases
|
|
RS62075B1
(sr)
|
2012-09-26 |
2021-07-30 |
Immunogen Inc |
Poboljšani postupak za acilaciju majtanzinola
|
|
SG10201702737TA
(en)
|
2012-10-04 |
2017-05-30 |
Immunogen Inc |
Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
|
|
AU2013337903B2
(en)
|
2012-10-30 |
2018-08-16 |
Apexigen, Inc. |
Anti-CD40 antibodies and methods of use
|
|
TW201425336A
(zh)
|
2012-12-07 |
2014-07-01 |
Amgen Inc |
Ｂｃｍａ抗原結合蛋白質
|
|
CN103333246B
(zh)
|
2012-12-21 |
2015-09-16 |
百奥泰生物科技(广州)有限公司 |
一种抗egfr受体的肿瘤生长抑制剂及其制备方法和用途
|
|
CN104530235A
(zh)
|
2012-12-21 |
2015-04-22 |
百奥泰生物科技(广州)有限公司 |
一种抑制肿瘤生长的抗体药物衍生物及其制备方法和用途
|
|
CN104688740A
(zh)
|
2012-12-21 |
2015-06-10 |
百奥泰生物科技(广州)有限公司 |
类美登素衍生物及其制备方法和用途
|
|
CN103254213B
(zh)
|
2012-12-21 |
2015-02-25 |
百奥泰生物科技(广州)有限公司 |
类美登素酯的制备方法及用于所述方法的组合物
|
|
WO2014114801A1
(en)
|
2013-01-25 |
2014-07-31 |
Amgen Inc. |
Antibodies targeting cdh19 for melanoma
|
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
|
JP6436965B2
(ja)
|
2013-03-14 |
2018-12-12 |
ジェネンテック， インコーポレイテッド |
抗ｂ７−ｈ４抗体及びイムノコンジュゲート
|
|
JP6333943B2
(ja)
|
2013-03-15 |
2018-05-30 |
ノバルティス アーゲー |
抗体薬物コンジュゲート
|
|
KR102258460B1
(ko)
|
2013-05-30 |
2021-06-02 |
키닉사 파마슈티컬스, 리미티드 |
온코스타틴 m 수용체 항원 결합 단백질
|
|
EP3013365B1
(en)
|
2013-06-26 |
2019-06-05 |
Academia Sinica |
Rm2 antigens and use thereof
|
|
EP3013347B1
(en)
|
2013-06-27 |
2019-12-11 |
Academia Sinica |
Glycan conjugates and use thereof
|
|
EP3022224A2
(en)
|
2013-07-18 |
2016-05-25 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
|
US10640574B2
(en)
|
2013-07-18 |
2020-05-05 |
Taurus Biosciences, Llc |
Humanized antibodies with ultralong complementary determining regions
|
|
EP3738612A1
(en)
|
2013-07-31 |
2020-11-18 |
Biontech AG |
Diagnosis and therapy of cancer involving cancer stem cells
|
|
CN104341504B
(zh)
|
2013-08-06 |
2017-10-24 |
百奥泰生物科技(广州)有限公司 |
双特异性抗体
|
|
EP3041484B1
(en)
|
2013-09-06 |
2021-03-03 |
Academia Sinica |
Human inkt cell activation using glycolipids with altered glycosyl groups
|
|
CA2922562A1
(en)
|
2013-09-12 |
2015-03-19 |
Halozyme, Inc. |
Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
|
|
JP2016537399A
(ja)
|
2013-09-17 |
2016-12-01 |
ジェネンテック， インコーポレイテッド |
抗ｌｇｒ５抗体を使用する方法
|
|
EP3054987B1
(en)
|
2013-10-11 |
2019-10-09 |
The United States of America, represented by the Secretary, Department of Health and Human Services |
Tem8 antibodies and their use
|
|
EP3066118B1
(en)
|
2013-11-06 |
2020-01-08 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Alk antibodies, conjugates, and chimeric antigen receptors, and their use
|
|
US9562059B2
(en)
*
|
2013-12-02 |
2017-02-07 |
Hong Kong Baptist University |
Anticancer maytansinoids with two fused macrocyclic rings
|
|
CA2931340A1
(en)
|
2013-12-13 |
2015-06-18 |
Genentech, Inc. |
Anti-cd33 antibodies and immunoconjugates
|
|
CR20160271A
(es)
|
2013-12-16 |
2016-12-02 |
Genentech Inc |
Compuestos peptidométicos y sus conjugados de anticuerpo-fármaco
|
|
TW201620939A
(zh)
|
2014-01-16 |
2016-06-16 |
中央研究院 |
治療及檢測癌症之組合物及方法
|
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
|
RU2016130349A
(ru)
|
2014-01-24 |
2018-03-01 |
Дженентек, Инк. |
Способы применения антител против steap1 и иммуноконъюгатов
|
|
WO2015120075A2
(en)
|
2014-02-04 |
2015-08-13 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
|
EP3129767B1
(en)
|
2014-03-27 |
2021-09-01 |
Academia Sinica |
Reactive labelling compounds and uses thereof
|
|
CA2943299A1
(en)
|
2014-04-11 |
2015-10-15 |
Medimmune, Llc |
Bispecific her2 antibodies
|
|
KR102603417B1
(ko)
|
2014-05-06 |
2023-11-20 |
제넨테크, 인크. |
포유동물 세포를 사용한 이종다량체 단백질의 생산
|
|
JP2017522861A
(ja)
|
2014-05-22 |
2017-08-17 |
ジェネンテック， インコーポレイテッド |
抗ｇｐｃ３抗体及びイムノコンジュゲート
|
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
|
JP7093612B2
(ja)
|
2014-05-27 |
2022-06-30 |
アカデミア シニカ |
Ｂａｃｔｅｒｏｉｄｅｓ由来のフコシダーゼおよびそれを使用する方法
|
|
KR102512592B1
(ko)
|
2014-05-27 |
2023-03-21 |
아카데미아 시니카 |
항-ｈｅｒ2 글리코항체 및 이의 용도
|
|
KR20170003720A
(ko)
|
2014-05-27 |
2017-01-09 |
아카데미아 시니카 |
항-ｃｄ20 글리코항체 및 이의 용도
|
|
KR102494193B1
(ko)
|
2014-05-28 |
2023-01-31 |
아카데미아 시니카 |
항-ｔｎｆ-알파 글리코항체 및 이의 용도
|
|
BR112017001588A2
(pt)
|
2014-08-12 |
2017-11-21 |
Novartis Ag |
conjugados de anticorpo/fármaco anti-cdh6
|
|
KR102615681B1
(ko)
|
2014-08-28 |
2023-12-18 |
바이오아트라, 인코퍼레이티드 |
변형된 t 세포에 대한 조건부 활성 키메라 항원 수용체
|
|
EP3191500A4
(en)
|
2014-09-08 |
2018-04-11 |
Academia Sinica |
HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
|
|
CN113698485A
(zh)
|
2014-09-12 |
2021-11-26 |
基因泰克公司 |
抗-b7-h4抗体及免疫缀合物
|
|
MY186334A
(en)
|
2014-09-12 |
2021-07-12 |
Genentech Inc |
Anti-her2 antibodies and immunoconjugates
|
|
AR101846A1
(es)
|
2014-09-12 |
2017-01-18 |
Genentech Inc |
Anticuerpos anti-cll-1 e inmunoconjugados
|
|
US20160082120A1
(en)
|
2014-09-23 |
2016-03-24 |
Genentech, Inc. |
METHODS OF USING ANTI-CD79b IMMUNOCONJUGATES
|
|
EP3200829B1
(en)
|
2014-10-01 |
2023-12-06 |
Medimmune, LLC |
Method of conjugating a polypeptide
|
|
KR20170080675A
(ko)
|
2014-11-05 |
2017-07-10 |
제넨테크, 인크. |
항-fgfr2/3 항체 및 이의 이용 방법
|
|
WO2016087416A1
(en)
|
2014-12-03 |
2016-06-09 |
F. Hoffmann-La Roche Ag |
Multispecific antibodies
|
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
|
CA2972731A1
(en)
|
2015-01-24 |
2016-07-28 |
Chi-Huey Wong |
Cancer markers and methods of use thereof
|
|
TWI736523B
(zh)
|
2015-01-24 |
2021-08-21 |
中央研究院 |
新穎聚醣結合物及其使用方法
|
|
US10330683B2
(en)
|
2015-02-04 |
2019-06-25 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
|
WO2016145536A1
(en)
|
2015-03-18 |
2016-09-22 |
Immunobiochem Corporation |
Conjugates for the treatment of cancer targeted at intracellular tumor-associated antigens
|
|
WO2016165762A1
(en)
|
2015-04-15 |
2016-10-20 |
Ganymed Pharmaceuticals Ag |
Drug conjugates comprising antibodies against claudin 18.2
|
|
CN107787332B
(zh)
|
2015-04-24 |
2022-09-09 |
豪夫迈·罗氏有限公司 |
多特异性抗原结合蛋白
|
|
EP4286511A3
(en)
|
2015-06-12 |
2024-03-06 |
Lentigen Technology, Inc. |
Method to treat cancer with engineered t-cells
|
|
EP3310813A1
(en)
|
2015-06-17 |
2018-04-25 |
Novartis AG |
Antibody drug conjugates
|
|
CA2996205A1
(en)
|
2015-09-20 |
2017-03-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies specific for fibroblast growth factor receptor 4 (fgfr4) and methods of their use
|
|
CA3001306A1
(en)
|
2015-10-09 |
2017-04-13 |
Miltenyi Biotec Technology, Inc. |
Chimeric antigen receptors and methods of use
|
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
|
JP6991978B2
(ja)
|
2016-01-27 |
2022-02-03 |
メディミューン，エルエルシー |
定められるグリコシル化パターンを有する抗体を調製するための方法
|
|
CA3019952A1
(en)
|
2016-02-04 |
2017-08-10 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
|
CN109195996A
(zh)
|
2016-03-08 |
2019-01-11 |
中央研究院 |
N-聚醣及其阵列的模组化合成方法
|
|
WO2017161206A1
(en)
|
2016-03-16 |
2017-09-21 |
Halozyme, Inc. |
Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
|
|
US10961311B2
(en)
|
2016-04-15 |
2021-03-30 |
Macrogenics, Inc. |
B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof
|
|
KR20200087875A
(ko)
|
2016-04-15 |
2020-07-21 |
바이오아트라, 엘엘씨 |
항 Axl항체 및 이의 면역접합체와 이것들의 용도
|
|
WO2017196847A1
(en)
|
2016-05-10 |
2017-11-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
|
|
TW202434312A
(zh)
|
2016-05-13 |
2024-09-01 |
美商拜奧亞特拉公司 |
抗-ror2抗體、抗體片段、其免疫結合物及其用途
|
|
JP7022080B2
(ja)
|
2016-05-27 |
2022-02-17 |
ジェネンテック， インコーポレイテッド |
部位特異的抗体－薬物複合体の特徴付けのための生化学分析的方法
|
|
WO2017214182A1
(en)
|
2016-06-07 |
2017-12-14 |
The United States Of America. As Represented By The Secretary, Department Of Health & Human Services |
Fully human antibody targeting pdi for cancer immunotherapy
|
|
EP3494135A1
(en)
|
2016-08-02 |
2019-06-12 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Monoclonal antibodies targeting glypican-2 (gpc2) and use thereof
|
|
JP7213549B2
(ja)
|
2016-08-22 |
2023-01-27 |
シーエイチオー ファーマ インコーポレイテッド |
抗体、結合性断片、および使用の方法
|
|
CN117298260A
(zh)
|
2016-09-02 |
2023-12-29 |
莱蒂恩技术公司 |
用DuoCAR治疗癌症的组合物和方法
|
|
GB201615725D0
(en)
|
2016-09-15 |
2016-11-02 |
Polytherics Ltd |
Novel cytotoxic agents and conjugates thereof
|
|
US11697680B2
(en)
|
2016-11-21 |
2023-07-11 |
Cureab Gmbh |
Anti-GP73 antibodies and immunoconjugates
|
|
EP3559038B1
(en)
|
2016-12-21 |
2022-12-14 |
The United States of America as represented by The Secretary Department of Health and Human Services |
Human monoclonal antibodies specific for flt3 and uses thereof
|
|
ES2936803T3
(es)
|
2017-01-09 |
2023-03-22 |
Lentigen Tech Inc |
Composiciones y métodos para tratar el cáncer con inmunoterapia antimesotelina
|
|
JOP20190187A1
(ar)
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
مترافقات عقار جسم مضاد لـ ccr7
|
|
CN110997719B
(zh)
|
2017-03-24 |
2020-12-11 |
莱蒂恩技术公司 |
用于用抗cd33免疫疗法治疗癌症的组合物和方法
|
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
|
EP3625256A1
(en)
|
2017-05-19 |
2020-03-25 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Human monoclonal antibody targeting tnfr2 for cancer immunotherapy
|
|
AR111963A1
(es)
|
2017-05-26 |
2019-09-04 |
Univ California |
Método y moléculas
|
|
WO2019006280A1
(en)
|
2017-06-30 |
2019-01-03 |
Lentigen Technology, Inc. |
HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO CD33 AND METHODS OF USE
|
|
WO2019005208A1
(en)
|
2017-06-30 |
2019-01-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
|
|
AU2018309735A1
(en)
|
2017-07-31 |
2020-02-20 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD19/CD20 immunotherapy
|
|
CN107446050A
(zh)
|
2017-08-11 |
2017-12-08 |
百奥泰生物科技(广州)有限公司 |
Trop2阳性疾病治疗的化合物及方法
|
|
AU2018331517B2
(en)
|
2017-09-15 |
2024-10-03 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD19 immunotherapy
|
|
NZ762376A
(en)
|
2017-09-19 |
2022-08-26 |
Scherrer Inst Paul |
Transglutaminase conjugation method and linker
|
|
JP7275118B2
(ja)
|
2017-10-16 |
2023-05-17 |
レンティジェン・テクノロジー・インコーポレイテッド |
抗ｃｄ２２免疫療法によってがんを処置するための組成物および方法
|
|
EP3700540A4
(en)
|
2017-10-24 |
2021-11-10 |
Magenta Therapeutics, Inc. |
COMPOSITIONS AND METHODS OF DEPRODUCTION FROM CD117 + CELLS
|
|
CN111954677A
(zh)
|
2017-12-20 |
2020-11-17 |
莱蒂恩技术公司 |
用于用免疫治疗来治疗hiv/aids的组合物和方法
|
|
CA3105694A1
(en)
|
2018-07-12 |
2020-01-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Affinity matured cd22-specific monoclonal antibody and uses thereof
|
|
CN112739340A
(zh)
|
2018-07-23 |
2021-04-30 |
美真达治疗公司 |
抗cd5抗体药物缀合物(adc)在同种异体细胞疗法中的用途
|
|
CN112585163A
(zh)
|
2018-08-08 |
2021-03-30 |
美国政府(由卫生和人类服务部的部长所代表) |
靶向磷脂酰肌醇蛋白聚糖-2的高亲和力单克隆抗体及其用途
|
|
CA3113058A1
(en)
|
2018-09-20 |
2020-03-26 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd123 immunotherapy
|
|
CN118581122A
(zh)
|
2018-09-26 |
2024-09-03 |
莱蒂恩技术公司 |
用于用抗cd19/cd22免疫治疗来治疗癌症的组合物和方法
|
|
CA3121244A1
(en)
|
2018-11-30 |
2020-06-04 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd38 immunotherapy
|
|
AU2018451747A1
(en)
|
2018-12-06 |
2021-06-17 |
F. Hoffmann-La Roche Ag |
Combination therapy of diffuse large B-cell lymphoma comprising an anti-CD79b immunoconjugates, an alkylating agent and an anti-CD20 antibody
|
|
CA3125484A1
(en)
|
2019-01-08 |
2020-07-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cross-species single domain antibodies targeting mesothelin for treating solid tumors
|
|
CN113784987B
(zh)
|
2019-01-22 |
2024-09-13 |
美国政府(由卫生和人类服务部的部长所代表) |
靶向磷脂酰肌醇蛋白聚糖-1的高亲和力单克隆抗体和使用方法
|
|
CA3132660A1
(en)
|
2019-03-06 |
2020-09-10 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with self-driving chimeric antigen receptors
|
|
JP7629902B2
(ja)
|
2019-03-19 |
2025-02-14 |
パウル・シェラー・インスティトゥート |
グリシンベースリンカーを用いたトランスグルタミナーゼコンジュゲーション法
|
|
MX2021013825A
(es)
|
2019-05-14 |
2022-01-18 |
Genentech Inc |
Procedimientos de uso de inmunoconjugados anti-cd79b para tratar el linfoma folicular.
|
|
AU2020283027A1
(en)
|
2019-05-30 |
2021-12-23 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-BCMA immunotherapy
|
|
EP3994173A1
(en)
|
2019-07-02 |
2022-05-11 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Monoclonal antibodies that bind egfrviii and their use
|
|
EP3998083A4
(en)
|
2019-07-12 |
2023-08-23 |
Chugai Seiyaku Kabushiki Kaisha |
ANTI-MUTATION TYPE FGFR3 ANTIBODY AND USE THEREOF
|
|
EP4045090A1
(en)
|
2019-10-18 |
2022-08-24 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
|
CA3156761A1
(en)
|
2019-10-22 |
2021-04-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
High affinity nanobodies targeting b7h3 (cd276) for treating multiple solid tumors
|
|
JP2023506158A
(ja)
|
2019-12-12 |
2023-02-15 |
ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
Ｃｄ２７６に特異的な抗体－薬物コンジュゲートおよびその使用
|
|
AU2021259861A1
(en)
|
2020-04-24 |
2022-11-17 |
Genentech, Inc. |
Methods of using anti-CD79b immunoconjugates
|
|
US20230181756A1
(en)
|
2020-04-30 |
2023-06-15 |
Novartis Ag |
Ccr7 antibody drug conjugates for treating cancer
|
|
CA3171101A1
(en)
|
2020-06-22 |
2021-12-30 |
Dina SCHNEIDER |
Compositions and methods for treating cancer with tslpr-cd19 or tslpr-cd22 immunotherapy
|
|
EP4213886A1
(en)
|
2020-09-18 |
2023-07-26 |
Araris Biotech AG |
Transglutaminase conjugation method with amino acid-based linkers
|
|
MX2023004606A
(es)
|
2020-10-25 |
2023-05-08 |
Araris Biotech Ag |
Medios y metodos para producir conjugados de ligador-anticuerpo.
|
|
WO2022093745A1
(en)
|
2020-10-26 |
2022-05-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting sars coronavirus spike protein and uses thereof
|
|
CA3171093A1
(en)
|
2020-11-05 |
2022-05-12 |
Dina SCHNEIDER |
Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy
|
|
WO2022232612A1
(en)
|
2021-04-29 |
2022-11-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Lassa virus-specific nanobodies and methods of their use
|
|
CA3218170A1
(en)
|
2021-05-12 |
2022-11-17 |
Jamie Harue HIRATA |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
|
EP4347656A1
(en)
|
2021-05-28 |
2024-04-10 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination therapies for treating cancer
|
|
CA3216228A1
(en)
|
2021-06-09 |
2022-12-15 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cross species single domain antibodies targeting pd-l1 for treating solid tumors
|
|
US11807685B2
(en)
|
2021-08-05 |
2023-11-07 |
The Uab Research Foundation |
Anti-CD47 antibody and uses thereof
|
|
US20240336697A1
(en)
|
2021-08-07 |
2024-10-10 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
|
EP4412713A1
(en)
|
2021-10-05 |
2024-08-14 |
GlaxoSmithKline Intellectual Property Development Ltd |
Combination therapies for treating cancer
|
|
JP2024539989A
(ja)
|
2021-10-25 |
2024-10-31 |
アラリス バイオテック アーゲー |
抗体－リンカーコンジュゲートを生成する方法
|
|
EP4482529A1
(en)
|
2022-02-22 |
2025-01-01 |
Araris Biotech AG |
Peptide linkers comprising two or more payloads
|
|
US11590169B1
(en)
|
2022-03-02 |
2023-02-28 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD123 immunotherapy
|
|
US20230338424A1
(en)
|
2022-03-02 |
2023-10-26 |
Lentigen Technology, Inc. |
Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy
|
|
WO2024026107A2
(en)
|
2022-07-28 |
2024-02-01 |
Lentigen Technology, Inc. |
Chimeric antigen receptor therapies for treating solid tumors
|
|
WO2024044743A1
(en)
|
2022-08-26 |
2024-02-29 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with fully human anti-cd20/cd19 immunotherapy
|
|
WO2024218345A1
(en)
|
2023-04-21 |
2024-10-24 |
Glaxosmithkline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras for antibody-drug conjugates and bispecific antibodies
|
|
WO2024254455A1
(en)
|
2023-06-08 |
2024-12-12 |
Genentech, Inc. |
Macrophage signatures for diagnostic and therapeutic methods for lymphoma
|
|
WO2025014896A1
(en)
|
2023-07-07 |
2025-01-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Humanized 40h3 antibody
|
|
WO2025019228A1
(en)
|
2023-07-20 |
2025-01-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Fully human monoclonal antibodies and chimeric antigen receptors against cd276 for the treatment of solid tumors
|